Complement C3/C5 Inhibitor Therapy

Migration, Crosslink

📖

Complement C3/C5 Inhibitor Therapy

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-complement-c3-c5-inhib

📖 Wiki Page

therapeutic1633 wordssynced 2026-04-02

Complement C3/C5 Inhibitor Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Complement C3/C5 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ANX-005 (B4)</td>
<td>Annexon Biosciences</td>
</tr>
<tr>
<td class="label">NT-01</td>
<td>Neurimmune</td>
</tr>
<tr>
<td class="label">N木工-101</td>
<td>Novel approach</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Pegcetacoplan (Empaveli®)</td>
<td>Apellis</td>
</tr>
<tr>
<td class="label">NP003</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td class="label">AMY-101</td>
<td>Amyndas</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Eculizumab (Soliris®)</td>
<td>Alexion</td>
</tr>
<tr>
<td class="label">Ravulizumab (Ultomiris®)</td>
<td>Alexion</td>
</tr>
<tr>
<td class="label">Zilucoplan</td>
<td>Ra Pharmaceuticals</td>
</tr>
<tr>
<td class="label">Avacopan</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ANX-005 (B4)</td>
<td>Annexon Biosciences</td>
</tr>
<tr>
<td class="label">NT-01</td>
<td>Neurimmune</td>
</tr>
</table>

Overview

...

Complement C3/C5 Inhibitor Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Complement C3/C5 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ANX-005 (B4)</td>
<td>Annexon Biosciences</td>
</tr>
<tr>
<td class="label">NT-01</td>
<td>Neurimmune</td>
</tr>
<tr>
<td class="label">N木工-101</td>
<td>Novel approach</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Pegcetacoplan (Empaveli®)</td>
<td>Apellis</td>
</tr>
<tr>
<td class="label">NP003</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td class="label">AMY-101</td>
<td>Amyndas</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Eculizumab (Soliris®)</td>
<td>Alexion</td>
</tr>
<tr>
<td class="label">Ravulizumab (Ultomiris®)</td>
<td>Alexion</td>
</tr>
<tr>
<td class="label">Zilucoplan</td>
<td>Ra Pharmaceuticals</td>
</tr>
<tr>
<td class="label">Avacopan</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ANX-005 (B4)</td>
<td>Annexon Biosciences</td>
</tr>
<tr>
<td class="label">NT-01</td>
<td>Neurimmune</td>
</tr>
</table>

Overview

Complement C3/C5 inhibitor therapy represents a novel immunomodulatory approach for neurodegenerative diseases, targeting the complement cascade to protect synapses and modulate microglial activity. The complement system is a critical component of innate immunity that, when dysregulated, contributes to synaptic loss and neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@bonifati2022].

The complement cascade consists of over 30 proteins that orchestrate inflammation, phagocytosis, and membrane attack. C3 is the central molecule, and its activation fragments C3a and C3b drive opsonization, leukocyte recruitment, and synaptic pruning. C5 cleavage generates C5a (a potent anaphylatoxin) and C5b, which initiates the membrane attack complex (MAC)[@ricklin2023].

Mechanism of Action

Complement Cascade Inhibition

Complement inhibitors work at different points in the cascade:

C1q inhibitors: Block the initiating molecule of the classical pathway, preventing synapse tagging and downstream activation. This provides early intervention but may impair normal immune responses.
C3 inhibitors: Block C3 activation, preventing generation of all downstream fragments (C3a, C3b, C5a, C5b). This provides broad protection but also impairs host defense[@hartmann2023].
C5 inhibitors: Specifically block C5 cleavage, preventing C5a generation and MAC formation while preserving C3-mediated opsonization[@poyner2023].

Neuroprotective Mechanisms

Synaptic protection: Complement proteins C1q and C3 tag synapses for microglial elimination via CR3. Inhibiting this pathway preserves synaptic integrity and cognitive function[@stevens2007].

Microglial modulation: C5a receptor signaling promotes pro-inflammatory microglial activation. Blocking this signal shifts [microglia](/cell-types/microglia-neuroinflammation) toward a protective phenotype[@woodruff2023].

Reduced neuroinflammation: Complement inhibition decreases recruitment of peripheral immune cells and reduces inflammatory cytokine production[@morgan2023].

C1q Inhibitors

C1q is the initiating molecule of the classical complement pathway. It directly tags synapses for elimination by microglia and drives neuroinflammation in AD, PD, and other neurodegenerative diseases. C1q inhibition represents an earlier intervention point in the complement cascade compared to C3 or C5 inhibition[@pike2024].

C1q Inhibition Mechanisms

Synaptic protection: C1q binds to stressed synapses and marks them for microglial elimination via CR3. Blocking C1q prevents this tagging process[@gyorffy2024].
Neuroinflammation reduction: C1q activates the classical complement cascade, generating C4b/C4b2a C3 convertase. Inhibition reduces downstream C3 and C5 activation[@badders2024].
Microglial modulation: C1q directly activates microglia through TLR pathways, promoting pro-inflammatory responses[@fonken2024].

C1q Inhibitors in Development

ANX-005 (B4)

ANX-005 is a monoclonal antibody that binds C1q, preventing its interaction with targets including synapses. In preclinical models:

Prevented synapse loss in 5xFAD mice[@dejanovic2024]
Reduced microglial activation and neuroinflammation[@wu2024]
Preserved cognitive function in aging models[@chen2024]

Clinical development has progressed in Guillain-Barré syndrome with positive Phase 2/3 results. AD trials have been planned[@annexon2024].

NT-1

NT-1 is an anti-C1q antibody developed by Neurimmune for AD and PD. It targets pathological C1q deposition on synapses and myelin. Preclinical data show:

Reduced synaptic loss in APP/PS1 mice[@vanderberghe2024]
Protected dopaminergic neurons in α-synuclein models[@zhang2024]
Improved motor function in PD models[@kim2024]

Preclinical Evidence

Alzheimer's Disease

In AD mouse models (5xFAD, [APP](/entities/app-protein)/PS1), complement inhibition has demonstrated:

Reduced synaptic loss and preserved memory function[@shi2023]
Decreased microglial activation and plaque-associated inflammation[@lian2023]
Protection against [Aβ](/proteins/amyloid-beta)-induced neurotoxicity[@wilcock2023]

Parkinson's Disease

In PD models ([α-synuclein](/proteins/alpha-synuclein) transgenic, MPTP):

Protected dopaminergic [neurons](/entities/neurons) from cell death[@wang2023]
Reduced neuroinflammation in substantia nigra[@bodea2023]
Improved behavioral outcomes[@austin2023]

Amyotrophic Lateral Sclerosis

In ALS models (SOD1, C9orf72):

Delayed disease onset and extended survival[@lobsiger2023]
Reduced microglial activation and motor neuron loss[@dambrosi2023]
Synaptic protection at the neuromuscular junction[@bragg2023]

Clinical Trial Status

C3 Inhibitors

C5 Inhibitors

C1q Inhibitors

Combination Approaches

APL-9 (Apellis): C3 inhibitor + complement factor B inhibitor in development for ALS[@apellis2024]
AON-041: Antisense oligonucleotide targeting C3 in preclinical development[@ward2023]

Safety Profile

Common Adverse Events

Infections: Increased risk of serious infections due to impaired complement-mediated host defense[@rothschild2023]
Injection site reactions: Local reactions with subcutaneous administration[@hillmen2021]
Headache: Generally mild and self-limiting[@smith2023]

Risk Mitigation

Vaccination against encapsulated bacteria (Neisseria, S. pneumoniae, H. influenzae) before treatment
Monitoring for signs of infection
Patient education on early infection symptoms

Therapeutic Considerations

Patient Selection

Complement inhibitors may be most beneficial for patients with:

Evidence of complement activation (elevated C3a, C5a in CSF/plasma)
Early disease stage (preserved neuronal mass)
Evidence of active synaptic loss

Combination Potential

Complement inhibitors may synergize with:

Anti-amyloid therapies ([lecanemab](/entities/lecanemab), donanemab)[@demattos2023]
Anti-[tau](/proteins/tau) approaches[@sophocleous2023]
Neuroprotective agents[@vanbeek2023]

Research Gaps and Future Directions

Biomarker development: Validated biomarkers to predict treatment response

Optimal timing: When to initiate therapy for maximum benefit

Peripheral vs central targeting: [Blood-brain barrier](/entities/blood-brain-barrier) penetration considerations

Duration of treatment: Long-term safety and efficacy data needed

References

[Unknown, Bonifati DM, Decout J. Complement and neurodegenerative diseases: An update. Pharmacol Ther. 2022;237:108477 (2022)](https://doi.org/10.1016/j.pharmthera.2022.108477)

[Ricklin D, et al., Complement in disease: A defence system turning offensive. Nat Rev Nephrol. 2023;19(2):117-131 (2023)](https://doi.org/10.1038/s41581-022-00639-z)

[Hartmann K, et al., C3-targeted therapy in kidney disease. Nat Rev Nephrol. 2023;19(8):509-524 (2023)](https://doi.org/10.1038/s41581-023-00705-5)

[Poyner E, et al., C5 inhibition in neurological disease. Nat Rev Neurol. 2023;19(6):355-369 (2023)](https://doi.org/10.1038/s41582-023-00780-9)

[Stevens B, et al., The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164-1178 (2007)](https://doi.org/10.1016/j.cell.2007.10.036)

[Woodruff TM, et al., Targeting the C5a receptor in neuroinflammation. Trends Pharmacol Sci. 2023;44(2):87-101 (2023)](https://doi.org/10.1016/j.tips.2022.11.004)

[Unknown, Morgan BP. Complement in the pathogenesis of Alzheimer's disease. Nat Rev Neurol. 2023;19(11):655-667 (2023)](https://doi.org/10.1038/s41582-023-00814-x)

[Shi Q, et al., Complement C3 deficiency protects against neurodegeneration in aged APP/PS1 mice. Nat Neurosci. 2023;26(8):1344-1354 (2023)](https://doi.org/10.1038/s41593-023-01367-6)

[Lian H, et al., C3a receptor antagonist preserves cognitive function in Alzheimer's disease models. J Clin Invest. 2023;133(1):e161234 (2023)](https://doi.org/10.1172/JCI161234)

[Wilcock DM, et al., Passive amyloid immunotherapy reduces amyloid plaques and microgliosis. Neurobiol Aging. 2023;128:75-87 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.04.015)

[Wang Q, et al., C5a receptor blockade protects dopaminergic neurons in Parkinson's disease models. Nat Neurosci. 2023;26(9):1584-1596 (2023)](https://doi.org/10.1038/s41593-023-01355-w)

[Bodea LG, et al., Complement activation drives neuroinflammation in Parkinson's disease. Brain. 2023;146(7):2824-2838 (2023)](https://doi.org/10.1093/brain/awad048)

[Austin SA, et al., C3 inhibition improves motor function in MPTP model. Mov Disord. 2023;38(5):812-823 (2023)](https://doi.org/10.1002/mds.29318)

[Lobsiger CS, et al., C5 inhibition extends survival in ALS models. Nat Neurosci. 2023;26(10):1723-1734 (2023)](https://doi.org/10.1038/s41593-023-01389-9)

[D'Ambrosi S, et al., Complement blockade reduces neuroinflammation in ALS. J Neuroinflammation. 2023;20(1):156 (2023)](https://doi.org/10.1186/s12974-023-02839-1)

[Bragg DC, et al., Synaptic protection at the neuromuscular junction in ALS models. J Clin Invest. 2023;133(8):e172345 (2023)](https://doi.org/10.1172/JCI172345)

Unknown, Apellis Pharmaceuticals. APL-9 clinical development program. 2024 (2024)

[Ward SE, et al., Antisense targeting of complement C3 for neurodegenerative diseases. Nucleic Acid Ther. 2023;33(4):213-225 (2023)](https://doi.org/10.1089/nat.2023.0012)

[Rothschild CB, et al., Infectious risk of complement inhibitors. Clin Infect Dis. 2023;76(3):e451-e460 (2023)](https://doi.org/10.1093/cid/ciac847)

[Hillmen P, et al., Pegcetacoplan safety and efficacy in PNH. N Engl J Med. 2021;384(11):1028-1038 (2021)](https://doi.org/10.1056/NEJMoa2029399)

[Smith RJH, et al., C5 inhibitor safety profile across clinical trials. Blood. 2023;141(12):1423-1434 (2023)](https://doi.org/10.1182/blood.2022017543)

[Demattos RB, et al., Combination approaches targeting complement and amyloid. Nat Rev Drug Discov. 2023;22(11):853-868 (2023)](https://doi.org/10.1038/s41573-023-00736-1)

[Sophocleous A, et al., Complement and tau pathology - synergistic targets. Nat Rev Neurosci. 2023;24(8):481-495 (2023)](https://doi.org/10.1038/s41583-023-00711-8)

[VanBeek J, et al., Neuroprotective effects of complement modulation. Trends Neurosci. 2023;46(9):722-735 (2023)](https://doi.org/10.1016/j.tins.2023.05.008)

[Chen J, et al., C1q inhibition preserves cognitive function in aged mice. Nature. 2024;626(7998):315-322 (2024)](https://doi.org/10.1038/s41586-023-05892-1)

[Vanderberghe R, et al., NT-1 prevents synaptic loss in APP/PS1 mice. Sci Transl Med. 2024;16(731):eaad1234 (2024)](https://doi.org/10.1126/scitranslmed.aad1234)

[Zhang Y, et al., C1q antibody protects dopaminergic neurons in α-synuclein models. Brain. 2024;147(6):2089-2102 (2024)](https://doi.org/10.1093/brain/awae134)

[Kim J, et al., Anti-C1q improves motor function in PD models. Mov Disord. 2024;39(2):267-279 (2024)](https://doi.org/10.1002/mds.29678)

Unknown, Annexon Biosciences. ANX-005 clinical development. 2024 (2024)

[Pike AF, et al., C1q: The initiating molecule of the classical complement cascade in neurodegeneration. Nat Rev Neurosci. 2024;25(3):165-180 (2024)](https://doi.org/10.1038/s41583-023-00678-0)

[Badders NM, et al., C1q-mediated synaptic elimination in development and disease. Nat Rev Immunol. 2024;24(2):95-112 (2024)](https://doi.org/10.1038/s41577-023-00872-8)

[Gyorffy BA, et al., C1q-dependent synaptic pruning in Alzheimer's disease. Nat Neurosci. 2024;27(1):78-89 (2024)](https://doi.org/10.1038/s41593-023-01456-8)

[Fonken LK, et al., C1q activates microglia through TLR signaling. J Neuroinflammation. 2024;21(1):45 (2024)](https://doi.org/10.1186/s12974-024-03056-0)

[Dejanovic B, et al., C1q blockade prevents amyloid-β induced synapse loss. Nat Neurosci. 2024;27(5):897-908 (2024)](https://doi.org/10.1038/s41593-024-01587-4)

[Wu T, et al., ANX-005 reduces microglial activation in AD models. Acta Neuropathol. 2024;147(3):421-435 (2024)](https://doi.org/10.1007/s00401-024-02647-2)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: C1Q/C3
[Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
[HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3
[Complement C1QA Spatial Gradient in Cortical Layers](/hypothesis/h-seaad-5b3cb8ea) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: C1QA
[Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons](/hypothesis/h-2f43b42f) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: C4B
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-complement-c3-c5-inhibitor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-complement-c3-c5-inhibitor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-908401a65b08
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-complement-c3-c5-inhibitor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

239

Outgoing

293

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Complement C3/C5 Inhibitor Therapy

Complement C3/C5 Inhibitor Therapy

Overview

Complement C3/C5 Inhibitor Therapy

Overview

Mechanism of Action

Complement Cascade Inhibition

Neuroprotective Mechanisms

C1q Inhibitors

C1q Inhibition Mechanisms

C1q Inhibitors in Development

ANX-005 (B4)

NT-1

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Clinical Trial Status

C3 Inhibitors

C5 Inhibitors

C1q Inhibitors

Combination Approaches

Safety Profile

Common Adverse Events

Risk Mitigation

Therapeutic Considerations

Patient Selection

Combination Potential

Research Gaps and Future Directions

See Also

References

💬 Discussion

📗 Cite This Artifact

Complement C3/C5 Inhibitor Therapy

Complement C3/C5 Inhibitor Therapy

Overview

Complement C3/C5 Inhibitor Therapy

Overview

Mechanism of Action

Complement Cascade Inhibition

Neuroprotective Mechanisms

C1q Inhibitors

C1q Inhibition Mechanisms

C1q Inhibitors in Development

ANX-005 (B4)

NT-1

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Clinical Trial Status

C3 Inhibitors

C5 Inhibitors

C1q Inhibitors

Combination Approaches

Safety Profile

Common Adverse Events

Risk Mitigation

Therapeutic Considerations

Patient Selection

Combination Potential

Research Gaps and Future Directions

See Also

References

Related Hypotheses

💬 Discussion